---
title: "Ozempic (semaglutide) in type 2 diabetes: Pharmacology questions"
description: "Pharmacology questions on Ozempic (semaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Ozempic work (mechanism of action)? How is Ozempic metabolized? How long does Ozempic stay in your system (half-life)? What are the inactive ingredients in Ozempic? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ozempic (semaglutide) in type 2 diabetes: Pharmacology questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Ozempic](https://www.novo-pi.com/ozempic.pdf), [Ozempic tablets](https://www.novo-pi.com/ozempictablets.pdf)

## Mechanism

<a id="ozempic-mechanism"></a>

### How does Ozempic work (mechanism of action)?

> “Glucagon-like peptide-1 (GLP-1) is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. Ozempic<sup>®</sup> acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.<sup>1,2</sup>
>
> How Ozempic<sup>®</sup> works in the body for T2D
>
> Stimulates insulin secretion
>
> Ozempic<sup>®</sup> lowers fasting and postprandial blood glucose by stimulating insulin secretion in a glucose-dependent manner. With Ozempic<sup>®</sup> injection, the insulin secretion rate in patients with type 2 diabetes was similar to that of healthy subjects.<sup>1,2</sup>
>
> Lowers glucagon secretion
>
> Ozempic<sup>®</sup> lowers glucagon secretion in a glucose-dependent manner.<sup>1,2</sup>
>
> Minor delay in gastric emptying
>
> Ozempic<sup>®</sup> causes a minor delay in gastric emptying, thereby reducing the rate at which glucose appears in circulation postprandially.<sup>1,2</sup>
>
> Ozempic<sup>®</sup> is a GLP-1 analog with 94% sequence homology to human GLP-1<sup>1,2</sup>
>
> Structural modifications of the Ozempic<sup>®</sup> molecule result in decreased renal clearance and protection from metabolic degradation.<sup>1,2</sup>”

Source: [OZEMPIC: Mechanism of Action, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/about/how-ozempic-works.html#:~:text=Glucagon%2Dlike%20peptide%2D1%20%28GLP%2D1%29%20is%20a,clearance%20and%20protection%20from%20metabolic)

> “The mechanism of kidney-related risk reduction has not been established.”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=4)

## Pharmacokinetics

<a id="ozempic-metabolism"></a>

### How is Ozempic metabolized?

> “Metabolism
> The primary route of elimination for semaglutide is metabolism following proteolytic cleavage of 
> the peptide backbone and sequential beta-oxidation of the fatty acid sidechain.
> Excretion
> The primary excretion routes of semaglutide-related material are via the urine and feces. 
> Approximately 3% of the dose is excreted in the urine as intact semaglutide.”

Source: [OZEMPIC: Ozempic®, page 5, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=5)

> “Metabolism: The primary route of elimination for semaglutide is metabolism following proteolytic 
> cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain.
> Excretion: The primary excretion routes of semaglutide-related material are via the urine and feces. 
> Approximately 3% of the absorbed dose is excreted in the urine as intact semaglutide.”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=6)

Note: The first passage is from the Ozempic® injection Prescribing Information; the second is from the Prescribing Information for semaglutide tablets.

<a id="ozempic-half-life"></a>

### How long does Ozempic stay in your system (half-life)?

> “With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation 
> for about 5 weeks after the last dose.”

Source: [OZEMPIC: Ozempic®, page 5, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=5)

> “Steady-state exposure is achieved following 4 to 
> 5 weeks of once-weekly administration.”

Source: [OZEMPIC: Ozempic®, page 5, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=5)

> “Semaglutide elimination half-life is approximately one week with an absolute clearance of approximately 
> 0.04 L/hour in patients with type 2 diabetes. Semaglutide is present in the circulation for about five 
> weeks after the last semaglutide tablet dose.”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=6)

Note: The first two passages are from the Ozempic® injection Prescribing Information; the third is from the Prescribing Information for semaglutide tablets.

## Components

<a id="ozempic-inactive-ingredients"></a>

### What are the inactive ingredients in Ozempic?

> “OZEMPIC<sup>®</sup> is a sterile, aqueous, clear, colorless solution. Each 3 mL prefilled, single-patient-use 
> pen contains semaglutide 2 mg (0.68 mg/mL), 4 mg (1.34 mg/mL), or 8 mg (2.68 mg/mL). Each 1 
> mL of OZEMPIC<sup>®</sup> solution also contains the following inactive ingredients: disodium phosphate 
> dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injections. OZEMPIC<sup>®</sup> 
> has a pH of approximately 7.4. Hydrochloric acid or sodium hydroxide may be added to adjust pH. 
> Each 0.5 mL single-dose syringe contains a solution of OZEMPIC<sup>®</sup> containing 0.25 mg, 0.5 mg 
> or 1 mg of semaglutide. Each 1 mL of OZEMPIC<sup>®</sup> contains the following inactive ingredients: 
> disodium phosphate dihydrate, 1.42 mg; sodium chloride, 8.25 mg; and water for injection. 
> OZEMPIC<sup>®</sup> has a pH of approximately 7.4. Hydrochloric acid or sodium hydroxide may be added 
> to adjust pH.”

Source: [OZEMPIC: Ozempic®, page 4, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=4)

> “OZEMPIC<sup>®</sup> tablets contain 1.5 mg, 4 mg or 9 mg of semaglutide and the following inactive ingredients: 
> magnesium stearate and SNAC.”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=6)

Note: The first passage is from the Ozempic® injection Prescribing Information; the second is from the Prescribing Information for semaglutide tablets.

## Related pages
- [Medical information: Ozempic (semaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/access-and-coverage)
